retatrutide obesity phase 2 trial Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 conducted in the USA Retatrutide for the treatment of

Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1

Understanding the complex relationship between weight loss medications and sexual health helps patients and clinicians make informed treatment decisions

1mg dose: 8.7% average weight loss 4mg dose: 15.2% average weight loss 8mg dose: 21.1% average weight loss 12mg dose: 24.2% average weight loss Placebo: 2.1% average weight loss For practical context, a person starting at 220 pounds would lose approximately 53 pounds at the highest dose over 48 weeks

If diet and exercise do not change, the shot alone is not expected to move the scale

With astounding results indicating weight loss of up to 28.3% at 80 weeks, it outperformed many current therapies

Retatrutide is an unlicensed investigational medicine, and no formal interaction studies with NAD+ precursors have been conducted